UQ and AbGenics partner to develop new drugs against antimicrobial resistance

UQ researchers have been awarded almost $1 million through the Australia-India Strategic Research Fund (AISRF) to combat the threat of antimicrobial resistance to human health.

Led by Professor Mark Blaskovich from the Institute for Molecular Bioscience, the project will combine research from UQ and AbGenics Life Sciences in India to support the development of new drugs and diagnostics to address this global challenge.

UQ researchers will characterise antibodies developed by AbGenics and create derivatives with enhanced abilities to detect and kill bacteria.

The AISRF supports collaboration between Australia and India's leading universities, research institutions and the end users of scientific innovation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Is fruit juice good or bad for diabetes? New research reveals a genetic twist